摘要
目的运用网络药理学方法,研究四妙勇安汤在“异病同治”理论指导下治疗冠状动脉粥样硬化性心脏病和血栓闭塞性脉管炎的共同机制。方法通过TCMSP数据库检索四妙勇安汤中4味中药相关的所有单体和作用靶点,运用UniProt数据库进行标准化,并用Cytoscape 3.7.2软件构建“中药-化合物-靶点”作用网络;通过GeneCards和NCBI数据库获取冠状动脉粥样硬化性心脏病和血栓闭塞性脉管炎的相关基因,并与药物作用靶点取交集,利用Cytoscape 3.7.2软件构建三者的靶点关联网络;输入共有靶点于STRING数据库,构建PPI网络;进行GO(gene ontology)与KEGG通路富集分析(Kyoto encyclopedia of genes and genomes)。结果根据口服生物利用度为≥30%和类药性指数为≥0.18,筛选得四妙勇安汤活性化合物,计120个,并预测到205个潜在靶点,对两种疾病共有靶点共48个。GO功能富集生物过程条目计46项(P<0.01),同时在KEGG通路富集分析筛选上有147条信号通路(P<0.01),其中靠前的多条信号通路与免疫炎症密切相关。结论该研究表明四妙勇安汤主要是通过调控炎症相关信号通路达到“异病同治”冠状动脉粥样硬化性心脏病和血栓闭塞性脉管炎的主要机制,并通过荟萃分析证实其“异病同治”的疗效和炎症调节作用。
Objective To explore the mechanism of Simiaoyong’an Decoction in treating atherosclerotic heart disease and thromboangiitis obliterans through the theory of"same treatment to different diseases"by using network pharmacology Methods The TCMSP database was used to retrieve all of monomers and targets related to the four herbs in Simiaoyong’an Decoction.The database of UniProt was used for standardization.Meanwhile,Cytoscape 3.7.2 was used to build"traditional Chinese medicine-compound-target"action network;we used genecards and NCBI database to obtain the related genes of atherosclerotic heart disease and thromboangiitis obliterans,and took intersection with drug and targets,then used Cytoscape 3.7.2 to build the target association network of the them.PPI network with common target was built by the database of string.Gene Ontology and KEGG pathway enrichment analysis were carried out.Results According to the oral bioavailability≥30%and drug like index≥0.18,120 active compounds of Simiaoyong’an Decoction were screened,and 205 potential targets were predicted.There were 48 common targets for the two diseases from the decoction.There were 46 items of go functional enrichment in biological process(P<0.01).Meanwhile,147 signal pathways(P<0.01)were obtained through KEGG pathway enrichment analysis,and multiple signal paths in the front of which were closely related to inflammation.Conclusion This study showed the main mechanism of Simiaoyong’an Decoction in treating atherosclerotic heart disease and thromboangiitis obliterans by regulating inflammation related signaling pathways,and meta-analysis confirmed the efficacy of"same treatment to different diseases"and its role in inflammation regulation.
作者
童宏选
柏冬
江丽杰
唐碧华
汪锦城
胡镜清
Tong Hongxuan;Bai Dong;Jiang Lijie;Tang Bihua;Wang Jincheng;Hu Jingqing(Institute of Basic Theory for Traditional Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第11期3907-3917,共11页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家科学技术部国家重点研发计划(2019YFC1708501):冠心病痰瘀互结病因病机与诊治方案创新研究,负责人:胡镜清
国家自然科学基金委员会面上课题(82074316):血栓闭塞性脉管炎到冠心病的异病同治与TLR4信号通路,负责人:胡镜清
中国中医科学院中央级公益性科研院所基本科研业务费专项资金资助项目(YZ-1802):加味四妙勇安汤治疗冠心病、高血压病、脉管炎的临床疗效评价关键问题研究,负责人:江丽杰。
关键词
四妙勇安汤
网络药理学
冠状动脉粥样硬化性心脏病
血栓闭塞性脉管炎
异病同治
Simiaoyong’an Decoction
Network pharmacology
Coronary atherosclerotic heart disease
Thromboangiitis obliterans
Theory of"same treatment to different diseases"
作者简介
通讯作者:胡镜清,医学博士,研究员,博士研究生导师,主要研究方向:中医药理论构筑和诊疗模式临床研究方法的适用研究。
